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The most common malignant tumour of the breast is
carcinoma. Other malignancies account for less than 1% of
primary malignant mammary neoplasms. Malignant lym-
phoma is relatively rare in the breast but may occur as part
of disseminated disease or occasionally arise as a primary
lesion within mammary tissue.
Differential diagnosis between primary lymphoma and
carcinoma is usually not possible on clinical and mammo-
graphic grounds. Histological differentiation, particularly
from some patterns of infiltrating lobular carcinoma, can
also be difficult on purely morphological appearance. Use of
well defined tumour markers has facilitated accurate diag-
nosis of tumours of uncertain origin and has refined the
classification of lymphomas. The importance of differentiat-
ing between mammary carcinoma and lymphoma lies in the
different behaviour of the neoplasms and, therefore, different
approach to therapy.
Here we present a case of primary malignant lymphoma of
the breast which was initially diagnosed as disseminated
anaplastic mammary carcinoma and treated with tamoxifen.
Subsequent immunohistochemistry identified the lympho-
matous nature of the tumour but, as the patient was by then
showing evidence of response to tamoxifen, treatment was
continued resulting in long-term, complete remission.
Mrs J. L, a 50 year old woman, presented with a four month history
of pain and swelling of the left breast. On examination a 4.5cm
mass was present in the upper outer quadrant of the left breast. The
lesion had a smooth surface and was freely mobile with no evidence
of attachement to either skin or deep structures. Attempted aspi-
ration produced 15ml of altered blood but the mass remained.
Mammography showed the lesion to have a smooth, well defined
outline. Multiple bilateral pulmonary secondaries were evident on
chest radiograph. The patient was parous having had one child at
the age of 36 years, which she did not breast feed. She had never
taken oral contraceptives. She was premenopausal at presentation
with regular periods but these were scanty and she had been
experiencing hot flushes for the previous year.
The mass in the breast was excised and histological examination
showed an unusual neoplasm with a variety of patterns. For the
most part, it consisted of sheets of cells with open nuclei, prominent
nucleoli and moderate amounts of eosinophilic cytoplasm. Nuclear
pleomorphism was moderate and there was a high mitotic rate. In
some areas numerous multinucleated giant cells were present scat-
tered amongst the sheets of cells (Figure 1). In other areas the
tumour was composed of bundles of spindle shaped cells showing
moderate nuclear pleomorphism but with a lower mitotic rate
(Figure 2). Areas of apparent transition between the two patterns
were seen (Figure 3). There were large areas of necrosis and a heavy
inflammatory cell reaction, consisting mainly of lymphocytes and
plasma cells, was present focally. Malignant cells could be seen
infiltrating the fat around the periphery of the tumour. Occasional
epithelial elements were present within the lesion but these appeared
quite benign and probably represented normal mammary glandular
components which had been engulfed by the neoplasm. At one end
of the tumour a benign fibroadenoma was recognisable.
These appearances were initially interpreted as representing an
unusual metaplastic carcinoma with a pseudosarcomatous compo-
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nent. Assay for oestrogen receptor was positive (13 fmolg-1 protein)
and progesterone receptor was negative. Because of the presence of
pulmonary secondaries it was decided to treat the patient with
tamoxifen 10mgbd. Within two weeks there was radiological evi-
dence of a decrease in size of the pulmonary metastases. This
improvement continued and after one year of treatment all radio-
logical signs of pulmonary secondaries had disappeared. Complete
resolution has been maintained now for 47 months and the patient
remains well and symptom free.
Following the initial histological diagnosis further tests were
carried out including extensive immunohistochemistry. The results
are summarised in Table I. Epithelial and neuroendocrine markers
were negative and histiocytic markers positive on the malignant cells
including the giant cells. An indirect immunoperoxidase technique
was employed using formalin fixed paraffin embedded tissue except
where stated.
Figure 1 H+E x 182. Section representative of the majority of
the neoplasm showing sheets of cells, including multinucleate
giant forms, with open nuclei, prominent nucleoli and moderate
amounts of cytoplasm. Scattered lymphocytes are also present.
Figure 2 H+E x 182. Section showing the spindle cell areas of
the neoplasm with moderate cellular pleomorphism and a single
multinucleated giant cell.
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Figure 3 H+E x 182. Section showing transition between the
two patterns shown in Figures 1 (top left) and 2 (bottom right).
In view of these findings and in association with the morpho-
logical appearance it was concluded that this was a pure histiocytic
lymphoma.
Primary malignant lymphoma of the breast is rare but
various histological types have been described, almost all
being non-Hodgkin's lymphoma. Only in recent years, how-
ever, has modern terminology been used (Telesinghe &
Anthony, 1985; Brustein et al., 1987; Dixon et al., 1987).
Furthermore as most of the cases previously described in the
literature have, by current standards, been inadequately
investigated, the exact phenotype of these lesions is uncer-
tain. In recent years the use of well characterised antibodies
in the evaluation of lymphomas has made accurate classifica-
tion possible. It has also become apparent that, with the
advent of well characterised markers to B- and T-cell
differentiation antigens, true histiocytic neoplasms are extre-
mely rare.
The neoplasm reported here presented a most unusual
histological appearance which did not immediately suggest
lymphoma. However, the degree of pleomorphism is, in
retrospect, consistent with the diagnosis of true histiocytic
lymphoma; marked pleomorphism with the presence of giant
cells being a well recognised feature of these rare neoplasms.
The diagnosis in this case probably could not have been
made without the use of immunohistochemical markers.
The unexpectedly good response obtained with tamoxifen
in this patient is of interest. One previous report
(Narasimhan, 1984) in the literature described a case of non-
Hodgkin's malignant lymphoma which responded to a
regime of tamoxifen only after failure on other forms of
therapy. The oestrogen receptor status of the tumour in that
report was not known. Assay of the present tumour for
oestrogen receptor was positive, albeit at a low level, and
progesterone receptor negative. Whether this is a common
feature of malignant lymphomas is not known and the
mesurement of receptor status of other such tumours would
be of interest.
This case report raises several points. The value of careful
evaluation by immunohistochemistry of anaplastic tumours
is illustrated. Accurate classification may well have an
important bearing on therapy. The current case also draws
attention to the very pleomorphic appearance that histiocytic
lymphoma may demonstrate. Finally, and perhaps most
important of all, this case raises the possibility that malig-
nant lymphomas may be hormonally responsive.
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Table I Results of immunohistochemistry
Staining of
Marker malignant cells Antigen/specificity Source
Epithelial
CAM 5.2 Keratins 8, 18, 19
LP34 Negative All epithelia Imperial Cancer
AuAl Epithelial associated Research Fund (ICRF)
membrane glycoprotein
Neuroendocrine
NSE Negative Neurone specific enolase DAKO
UJ13A NeaieFoetal calf brain ICRF
Common leucocyte Dr David Mason
PD7 Positive All leucocytes Oxford
Macrophage
a-l-Antitrypsin Present in macrophages DAKO
Lysozyme
Positive Dr David Jones S22 Recognise epitopes on Dr David Flavell
MAC 387 macrophages Southampton
HLA-DR Positiv a-chain determinant ICRF
IB5 of HLA-DR
B-cells
MB1 Negative Eurodiagnostics
Both fresh and B lymphocytes
LN1 fixed tissues ICN Biochemicals Ltd
T-cells
UCHL1 Negative Dr Peter Beverley
Both fresh and T lymphocytes London
MT1 fixed tissues Eurodiagnostics
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